Dr. Allison Weinkle, MD

Dr. Weinkle practices at Weinkle Dermatology, Inc. in Bradenton, Florida.

Dr. Weinkle's NPI, 1619323755, was assigned on May 8, 2016. Dr. Weinkle graduated from UC San Diego School of Medicine in 2016. Dr. Weinkle's California license number on file is A168686.

Dr. Weinkle's primary practice is Weinkle Dermatology, Inc., at 5601 21st W Ave, Bradenton, FL 34209 in Manatee County. The practice phone is (941) 794-5432.

Dr. Weinkle's primary practice is Weinkle Dermatology, Inc. in Bradenton, Florida. The medical group on file is Weinkle Dermatology. Dmand AI also links Dr. Weinkle to 1 more group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Weinkle practices, 2 sites in all. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Weinkle's primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dr. Weinkle is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Weinkle's licenses on file in 2 states: California and Florida.

Dmand AI lists acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, contact dermatitis, corns and calluses, facial skin infection, hives and itchy rashes among the conditions Dr. Weinkle treats.

CMS data shows 9,966 Medicare services from Dr. Weinkle across 34 procedure codes in 2024, for 1,792 Medicare patients. Medicare paid $593,716 for them. Every service was in an office.

CMS counts 1,792 Medicare patients who saw Dr. Weinkle in 2024. The largest group is 75 to 84, with 781 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 1% are also on Medicaid. Their average risk score is 1.17, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Weinkle's median patient age at 79, with 51% women.

In 2024, Dr. Weinkle wrote 733 Medicare Part D claims for 374 patients. 98% of them were for generic drugs. CMS names the drug for 641 of them, across 13 drugs with 11 or more claims each, at $8,564 in total drug cost. In 2023, CMS named 478 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Weinkle for performance year 2024, reported as part of a group. Dr. Weinkle accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 2,729 procedures of removal of skin lesions by Dr. Weinkle, more than 99% of the clinicians it reports for that procedure.

Dmand AI links 9 papers to Dr. Weinkle, published from 2016 to 2020. 2019 was the busiest year, with 2. The most frequent topics are Diagnosis, Differential, Biopsy and Dermatologic Agents. Dr. Weinkle has published most often in J Am Acad Dermatol. Dr. Weinkle's most frequent co-authors are Hilary E. Baldwin, MD, Brian Berman, MD, PhD and Brian A. Cahn, MD, MS.

CMS Open Payments shows 39 general payments to Dr. Weinkle from 14 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Allergan Inc. paid the most, $566.

Dr. Weinkle graduated from UC San Diego School of Medicine in 2016.

Dr. Weinkle is in network with 7 carriers, including Excellus BlueCross BlueShield, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.